Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | APAF1 | O14727 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | UBE2N | P61088 | 1/20 | 0.60 |
| ▸ | WHR1 | P49842 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8278143 | 0.88 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGDAPAF1POLB | |
| SCHEMBL5787992 | 0.83 | HTR2A (0.53) | KDM4EALDH1A1HPGDAPAF1POLB | |
| SCHEMBL5787458 | 0.82 | ALDH1A1 (0.53) | KDM4EALDH1A1HPGDHTR2AS1PR2 | |
| SCHEMBL5790102 | 0.81 | ALDH1A1 (0.69) | KDM4EALDH1A1HPGDMAPTHTR2A | |
| Hydrochloric Acid SCHEMBL5789717 | 0.80 | ALDH1A1 (0.67) | KDM4EALDH1A1HPGDMAPTHTR2A | |
| SCHEMBL5785682 | 0.80 | KDM4E (0.73) | KDM4EALDH1A1HPGDPOLBMAPT | |
| SCHEMBL5788948 | 0.78 | ALDH1A1 (0.64) | KDM4EALDH1A1HPGDAPAF1POLB | |
| SCHEMBL27062763 | 0.78 | ALDH1A1 (0.56) | KDM4EALDH1A1HPGDAPAF1POLB | |
| Hydrochloric Acid SCHEMBL5787241 | 0.77 | ALDH1A1 (0.63) | KDM4EALDH1A1HPGDAPAF1POLB | |
| SCHEMBL5788049 | 0.77 | ALDH1A1 (0.63) | KDM4EALDH1A1HPGDPOLBHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1755611-A1 | PHOSPHODIESTERASE 10 INHIBITION AS TREATMENT FOR OBESITY-RELATED AND METABOLIC SYNDROME-RELATED CONDITIONS | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005120514-A1 | PHOSPHODIESTERASE 10 INHIBITION AS TREATMENT FOR OBESITY-RELATED AND METABOLIC SYNDROME-RELATED CONDITIONS | PFIZER PRODUCTS INC. (US) | 2005-12-22 | — | — | WO | claimed |
| US-20090162286-A1 | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | PFIZER INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090162286-A1 | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | PFIZER INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090162286-A1 | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | PFIZER INC. | 2009-06-25 | — | — | US | disclosed |
| EP-1755611-A1 | PHOSPHODIESTERASE 10 INHIBITION AS TREATMENT FOR OBESITY-RELATED AND METABOLIC SYNDROME-RELATED CONDITIONS | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005120514-A1 | PHOSPHODIESTERASE 10 INHIBITION AS TREATMENT FOR OBESITY-RELATED AND METABOLIC SYNDROME-RELATED CONDITIONS | PFIZER PRODUCTS INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162286-A1 | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | PDE5A, PDE12, PDE2A | KDM4E 2074/4885ALDH1A1 1271/4885HPGD 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.